Sofinnova Ventures

Selected news for the capital firm - Sofinnova Ventures, collected since 11/2017. This capital firm shares healthcare news with Gilead, Genentech and several others.

Please provide a valid email address.
Shares Healthcare News With (link):
Companies

Selected Headines

Date Headline (link) Source Relevant Snippet
11/24/2020 Neurana Pharmaceuticals to Present at Piper Sandler 32nd Annual Healthcare Conference PR Newswire ... non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. In May 2018 , Neurana completed a $60 million Series A financing led by Sofinnova Ventures with participation from Longitude Capital, New Leaf Venture Partners and H.I.G. BioHealth Partners to fund the clinical development of tolperisone. For additional information, please visit www.neuranapharma.com .SOURCE Neurana Pharmaceuticals, Inc.Related Links http://www.neuranapharma.com ...
7/30/2020 Neurana Pharmaceuticals to Present at Upcoming Investor Conference PR Newswire ... non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. In May 2018 , Neurana completed a $60 million Series A financing led by Sofinnova Ventures with participation from Longitude Capital, New Leaf Venture Partners, H.I.G. BioHealth Partners, Hale BioPharma Ventures and MagnaSci Ventures to fund the clinical development of tolperisone. For additional information, please visit www.neuranapharma.com . SOURCE Neurana Pharmaceuticals ...
7/8/2020 VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology Business Wire ... Capital, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, and Wellington Management Company, which are joining existing investors Arix Bioscience, Decheng Capital, Pappas Capital, Sofinnova Ventures , and Takeda Ventures. The proceeds from the Series B financing will be used to further advance the clinical development of the VelosBio lead antibody-drug conjugate (ADC), VLS-101, and support the continued expansion ...
6/23/2020 Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics Business Wire ... respectively, are designed to selectively deplete and in some cases reprogram certain tumor-associated macrophages responsible for immunosuppression. Pionyr has raised $78 million from venture investors including New Enterprise Associates, OrbiMed, SV Health Investors, Sofinnova Ventures , Vida Ventures, Osage University Partners, Mission Bay Ventures, and Trinitas Ventures. For more information, please visit www.pionyrtx.com . About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes ...
6/8/2020 Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study PR Newswire ... non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. In May 2018 , Neurana completed a $60 million Series A financing led by Sofinnova Ventures with participation from Longitude Capital, New Leaf Venture Partners, H.I.G. BioHealth Partners, Hale BioPharma Ventures and MagnaSci Ventures to fund the clinical development of tolperisone. For additional information, please visit www.neuranapharma.com . SOURCE Neurana Pharmaceuticals ...
4/23/2020 Christopher & Dana Reeve Foundation Welcomes New Chairman PR Newswire ... in the pharmaceutical/biotech and drug delivery industries to his role as chairman. Prior to his retirement from Aravive, he was president and CEO of Versartis until its merger with Aravive; executive partner at Sofinnova Ventures ; president and CEO of both NextWave Pharmaceuticals (acquired by Pfizer) and Ilypsa, Inc. (acquired by Amgen); and interim president and CEO of Relypsa. In addition to his chairmanship at the Reeve Foundation, Shepard currently ...
2/26/2020 Neurana Pharmaceuticals to Participate in Cowen Health Care Conference PR Newswire ... non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. In May 2018 , Neurana completed a $60 million Series A financing led by Sofinnova Ventures with participation from Longitude Capital, New Leaf Venture Partners, H.I.G. BioHealth Partners, Hale BioPharma Ventures and MagnaSci Ventures to fund the clinical development of tolperisone. For additional information, please visit www.neuranapharma.com . SOURCE Neurana Pharmaceuticals ...
1/15/2020 Inovio Welcomes Biotech Leader to its Board of Directors PR Newswire ... and Chief Executive Officer of Aravive, a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Previously, Mr. Shepard was an Executive Partner at Sofinnova Ventures , a healthcare venture capital firm. Before that he also served as President and Chief Executive Officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company developing ...
11/7/2019 Neurana Pharmaceuticals Appoints Randall Kaye, M.D., Chief Medical Officer PR Newswire ... developing for the large population of patients in need of a treatment that does not cause drowsiness or impact cognitive function. In May 2018 , Neurana completed a $60 million Series A financing led by Sofinnova Ventures with participation from Longitude Capital, New Leaf Venture Partners, H.I.G. BioHealth Partners, Hale BioPharma Ventures and MagnaSci Ventures to fund the clinical development of tolperisone. For additional information, please visit www.neuranapharma.com . SOURCE Neurana Pharmaceuticals ...
8/14/2019 Sofinnova Ventures Inc Buys NextCure Inc, PTC Therapeutics Inc, Acceleron Pharma Inc, Sells ... gurufocus.com ... Coherus BioSciences Inc, Alnylam Pharmaceuticals Inc August 13, 2019 About: TGTX +0% HRTX +0% BMRN +0% HALO +0% RETA +0% NVO +0% NXTC +0% PTCT +0% XLRN +0% VRTX +0% B +0% Investment company Sofinnova Ventures Inc ( Current Portfolio ) buys NextCure Inc, PTC Therapeutics Inc, Acceleron Pharma Inc, Vertex Pharmaceuticals Inc, Bristol-Myers Squibb Company, sells AstraZeneca PLC, Coherus BioSciences Inc, Alnylam Pharmaceuticals Inc, AnaptysBio Inc, Xencor Inc during the ...
6/27/2019 Depressive Disorders Pipeline Review 2010-2019: 50% of Treated Patients do not Respond to the First Prescribed Antidepressant PR Newswire ... SK C & C SR One Salk Institute Sanford Burnham Prebys Medical Discovery Institute Sanofi Schering-Plough Schrdinger Servier Shanghai Medicilon Shenox Pharmaceuticals Shionogi Shire (acquired by Takeda Pharmaceutical) Silicon Valley Bank Sio Capital Management Sofinnova Ventures Solvay Sound Pharmaceuticals Subversive Capital Sumitomo Dainippon Pharma Sun Pharma Advanced Research Company Sunovion Pharmaceuticals Suven Life Sciences Takeda Pharmaceutical Targacept The Johns Hopkins University School of Medicine The Longevity Fund Third Rock Ventures ...
5/23/2019 AFYX Therapeutics Presents Framework for Patient-Reported Oral Lichen Planus Symptom Severity Measure at the 2019 American Academy of Oral Medicine Annual Conference PR Newswire ... Rivelin patch technology is able to adhere to mucosal surfaces, such as the mouth, to provide continuous and targeted therapeutic delivery for diseases where topical and other treatment modalities have proven inadequate. Investors include Sofinnova Ventures , Lundbeckfonden Emerge, Novo Seeds and Welfare Tech Invest. For additional information, please visit www.afyxtx.com . Corporate Communications Contact: Jason Spark Canale Communications (619) 849-6005 [email protected] SOURCE AFYX Therapeutics Related Links http://www.afyxtx.com ...
12/13/2017 Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment PR Newswire ... closing of a $62 million Series B investment round. This brings total funding since the company's founding in 2015 to $72 million . The Series B financing was led by New Enterprise Associates and included Sofinnova Ventures and Vida Ventures, along with Pionyr's existing investors, OrbiMed, SV Health Investors, Osage University Partners, and Mission Bay Ventures. Research conducted at Pionyr over the past year shows that its most advanced technology, Myeloid ...
12/13/2017 Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based PR Newswire ... closing of a $62 million Series B investment round. This brings total funding since the company's founding in 2015 to $72 million . The Series B financing was led by New Enterprise Associates and included Sofinnova Ventures and Vida Ventures, along with Pionyr's existing investors, OrbiMed, SV Health Investors, Osage University Partners, and Mission Bay Ventures. Research conducted at Pionyr over the past year shows that its most advanced technology, Myeloid ...
12/13/2017 Why this startup is playing in one of the hottest areas of cancer The Business Journals ... is heading into one of drug development's hottest spaces with a fresh round of $62 million. Pionyr Immunotherapeutics Inc. said Wednesday that its Series B round was led by New Enterprise Associates and included Sofinnova Ventures and Vida Ventures and involved existing investors OrbiMed, SV Health Investors, Osage University Partners and Mission Bay Ventures. The cash is earmarked for moving forward with two initial antibody treatments — pushing one by mid ...
11/27/2017 Medeor Therapeutics Raises $57 Million In Series B Financing PR Newswire ... company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies, today announced that it has closed an oversubscribed $57 million Series B financing, led by RA Capital Management. Additional new investors included Sofinnova Ventures and 6 Dimensions Capital, who were joined by existing investors Vivo Capital and WuXi Healthcare Ventures. In conjunction with the financing, Peter Kolchinsky , Ph.D., Portfolio Manager and Managing Director at RA Capital, and Anand ...
11/27/2017 Medeor Therapeutics Raises $57 Million In Series B Financing PR Newswire ... company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies, today announced that it has closed an oversubscribed $57 million Series B financing, led by RA Capital Management. Additional new investors included Sofinnova Ventures and 6 Dimensions Capital, who were joined by existing investors Vivo Capital and WuXi Healthcare Ventures. In conjunction with the financing, Peter Kolchinsky , Ph.D., Portfolio Manager and Managing Director at RA Capital, and Anand ...